Mitsubishi UFJ Morgan Stanley Securities’s Vertex Pharmaceuticals VRTX Stock Holding History

Mitsubishi UFJ Morgan Stanley Securities’s Portfolio VRTX Stock Details VRTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$75K	Sell	151 -262	-63%	-$116K	0.23%	71
2026 Q1	$184K	Sell	413 -41	-9%	-$19.1K	0.45%	143
2025 Q4	$206K	Buy	+454	New	+$196K	0.32%	106
2023 Q1	–	Sell	-100	Closed	-$29K	–	184
2022 Q4	$29K	Sell	100 -110	-52%	-$33.5K	0.25%	58
2022 Q3	$61K	Hold	210	–	–	0.82%	18
2022 Q2	$59K	Hold	210	–	–	0.08%	20
2022 Q1	$55K	Buy	210 +10	+5%	+$2.37K	0.05%	25
2021 Q4	$44K	Buy	+200	New	+$38.9K	0.02%	94
2014 Q4	$32K	Sell	270 -150	-36%	-$16.9K	0.07%	81
2014 Q3	$47K	Hold	420	–	–	0.13%	57
2014 Q2	$40K	Hold	420	–	–	0.12%	63
2014 Q1	$30K	Hold	420	–	–	0.08%	101
2013 Q4	$31K	Sell	420 -300	-42%	-$20.9K	0.05%	133
2013 Q3	$55K	Sell	720 -340	-32%	-$27.1K	0.09%	57
2013 Q2	$85K	Buy	+1,060	New	+$78.1K	0.28%	31

Other funds holding VRTX

Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.57% 1-Year Est. Return

Robeco Institutional Asset Management Rotterdam, Netherlands $81.4B AUM 40.71% 1-Year Est. Return

Swedbank Stockholm, Sweden $116B AUM 46.87% 1-Year Est. Return

Handelsbanken Fonder Stockholm, Sweden $35.1B AUM 47.76% 1-Year Est. Return

Mirae Asset Global Investments Seoul, South Korea $67.7B AUM 51.91% 1-Year Est. Return

Davenport & Co Richmond, Virginia $20.4B AUM 18.11% 1-Year Est. Return

New York State Teachers Retirement System (NYSTRS) Albany, New York $54.2B AUM 43.77% 1-Year Est. Return

FAF

Fjarde Ap-fonden Stockholm, Sweden $20.9B AUM 36.93% 1-Year Est. Return

BHIA

Birch Hill Investment Advisors Boston, Massachusetts $2.47B AUM 20.95% 1-Year Est. Return

Asset Management One Tokyo, Japan $39B AUM 37.51% 1-Year Est. Return

Mitsubishi UFJ Morgan Stanley Securities's VRTX Position: Q2 2026 in Review

Mitsubishi UFJ Morgan Stanley Securities reduced its Vertex Pharmaceuticals (VRTX) stake by 63% in Q2 2026, selling an estimated $116K and leaving 151 shares worth $75K. The position accounts for 0.23% of the portfolio, ranked #71.

Mitsubishi UFJ Morgan Stanley Securities first reported a position in VRTX in Q2 2013 and has held it in 15 quarters since. The position peaked at $206K in Q4 2025. 620 funds tracked by Wall St. Rank hold VRTX as of Q2 2026.

Mitsubishi UFJ Morgan Stanley Securities held 151 shares of Vertex Pharmaceuticals worth $75K as of Q2 2026.
Mitsubishi UFJ Morgan Stanley Securities sold 262 Vertex Pharmaceuticals shares in Q2 2026, an estimated $116K.
Vertex Pharmaceuticals made up 0.23% of Mitsubishi UFJ Morgan Stanley Securities's portfolio in Q2 2026, its #71 holding.
Mitsubishi UFJ Morgan Stanley Securities first reported a position in Vertex Pharmaceuticals in Q2 2013 and has held it in 15 quarters since.
Mitsubishi UFJ Morgan Stanley Securities's Vertex Pharmaceuticals position peaked at $206K in Q4 2025.
620 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q2 2026.

Based on Mitsubishi UFJ Morgan Stanley Securities's 13F filing for Q2 2026, filed 15 Jul 2026.